Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: More than a 24-month median follow-up

Journal of Orthopaedic Science

Volumn 17, Issue 6, 2012, Pages 770-774

  Takeda, Naoki ^a   Isu, Kazuo ^b   Hiraga, Hiroaki ^b   Shinohara, Nobuo ^c   Minami, Akio ^d   Kamata, Hajime ^e  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO CANCER CENTER   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e Hokuto Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUDA EQUINA SYNDROME; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PATHOLOGIC FRACTURE; RETREATMENT; RETROSPECTIVE STUDY; SPINAL CORD COMPRESSION; SURVIVAL TIME; THERAPY EFFECT; TREATMENT DURATION; BONE TUMOR; DISEASE FREE SURVIVAL; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84878992750     PISSN: 09492658     EISSN: 14362023     Source Type: Journal    
DOI: 10.1007/s00776-012-0294-9     Document Type: Article

References (17)

1. Tobisu K, Kakizoe T, Takai K, Tanaka Y. Prognosis in renal cell carcinoma: analysis of clinical course following nephrectomy. Jpn J Clin Oncol. 1989;19:142-8.
2. Toyada Y, Shinohara N, Harabayashi T, Abe T, Akino T, Sazawa A, Nonomura K. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol. 2007;52:163-9.
3. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patients survival after for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007;89:1794-801.
4. Kume H, Kakutani S, yamada Y, Shinohara M, Tominaga T, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Homma Y. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? J Urol. 2011;185:1611-4.
5. Fertil B, Malaise E. Intrinsic radiosensitivity of human cell lines is correlated with radio responsiveness of human tumors: analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys. 1985;11:1699-707.
6. Wilson D, Hiller L, Gray L, Grainger M, Stirling A, James N. The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin Oncol. 2003;15:400-7.
7. Lee J, Hodgson D, Chow E, Bezjak A, Catton P, Tsuji D, O'Brien M, Danjoux C, Hayter C, Warde P, Gospodarowicz MK. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer. 2005;104:1894-900.
8. DiBiase SJ, Valicent RK, Schultz D, Xie Y, Gomella LG, Corn BW. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol. 1997;158:746-9.
9. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-87.
10. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-44.
11. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003 15;21(16):3150-7.
12. Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases. Cancer. 2008;113:1438-45.
13. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962-9.
14. Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, Yonese J, Fukui I. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int. 2009;103:620-4.
15. Arrington SA, Damron TA, Mann KA, Allen WJ. Concurrent administration of zoledronic acid and irradiation leads to improved bone density, biomechanical strength, and micro architecture in a mouse model of tumor-induced osteolysis. J Surg Oncol. 2008;97:284-90.
16. Scavelli C, Di Pietro G, Cirulli T, Coluccia M, Boccarelli A, Giannini T, Mangialardi G, Bertieri R, Coluccia AM, Ribatti D, Dammacco F, Vacca A. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther. 2007;6:3256-62.
17. Yoneda Y, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen A, Taguchi A, Toyosawa S, Nagata T, Urade M. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010;28:365-83.